Health Care [ 5/12 ] | Biotechnology [ 19/75 ]
NASDAQ | Common Stock
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States.
The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and eosinophilic esophagitis which is in phase 1 clinical trial.
It also develops APG279 which is in phase 1 clinical trial for the treatment of atopic dermatitis; APG273 which is in phase 1 clinical trial for the treatment of asthma and chronic obstructive pulmonary disease; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases.
Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 10, 26 | -1.03 Increased by +12.71% | -0.62 Decreased by -66.13% |
| Nov 10, 25 | -1.11 Decreased by -28.61% | -0.61 Decreased by -81.97% |
| Aug 11, 25 | -1.13 Decreased by -88.33% | -0.62 Decreased by -82.26% |
| May 12, 25 | -0.95 Decreased by -48.44% | -0.58 Decreased by -63.79% |
| Mar 3, 25 | -1.18 Decreased by -268.75% | -0.62 Decreased by -90.32% |
| Nov 13, 24 | -0.86 Decreased by -69.24% | -0.56 Decreased by -54.12% |
| Aug 12, 24 | -0.60 Increased by +84.13% | -0.52 Decreased by -15.38% |
| May 13, 24 | -0.64 Increased by +73.11% | -0.61 Decreased by -4.92% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 0.00 Decreased by -100.00% | -69.39 M Decreased by -3.23% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 25 | 0.00 Decreased by N/A% | -65.02 M Decreased by -32.65% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 25 | 0.00 Decreased by N/A% | -66.10 M Decreased by -95.46% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by N/A% | -55.34 M Decreased by -72.43% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 130.00 K Increased by +N/A% | -67.22 M Decreased by -111.81% | Decreased by -51.71 K% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -49.02 M Decreased by -135.21% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -33.82 M Decreased by -79.06% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -32.09 M Decreased by -156.24% | Decreased by N/A% Decreased by N/A% |